Equity Analysis /
United States of America

US : Acceleron Pharma Inc. - XLRN | Highlights From NEJM Article and Editoral on Sotatercept's Phase 2 PULSAR Trial

    Daniil Gataulin
    Daniil Gataulin

    Ph.D., Sr. Res. Assoc.

    Follow
    CGS-CIMB
    1 April 2021
    Published byCGS-CIMB